Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Siemens Medical Solutions Diagnostics has signed an agreement with KreLo Medical Diagnostics for the rights to develop an automated stimulating TSH receptor antibody assay used in the differential diagnosis of Graves' disease.
Subscribe to our email newsletter
This agreement is said to make Siemens Medical Solutions Diagnostics the first in vitro diagnostics distributor of an automated TSH receptor antibody (TRAb) assay featuring stimulating TRAb KreLo antibodies, which are specific to the diagnosis of Graves’ disease.
Studies have shown that the TRAb test has the highest diagnostic power to differentiate Graves’ disease from toxic nodular goiters.
Joe Bernardo, senior vice president, central lab testing, Siemens Medical Solutions Diagnostics, said: “The new TRAb assay has enormous potential to help diagnose, monitor and predict the course of Graves’ disease.”